Harshad R Kulkarni
Overview
Explore the profile of Harshad R Kulkarni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
3295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bodei L, Cremonesi M, Ferrari M, Mittra E, Kulkarni H, Deroose C, et al.
J Nucl Med
. 2025 Feb;
66(3):449-456.
PMID: 39947918
This substudy of the phase III NETTER-1 trial evaluated [Lu]Lu-DOTATATE (hereafter Lu-DOTATATE) for advanced midgut neuroendocrine tumors and aimed to assess dosimetry of a standard 4-cycle protocol and any potential...
2.
Liu G, Gu Y, Sollini M, Lazar A, Besson F, Li S, et al.
Eur J Nucl Med Mol Imaging
. 2024 Nov;
52(3):1038-1049.
PMID: 39520515
Purpose: Positron emission tomography/computed tomography (PET/CT) imaging has been widely used in clinical practice. Long axial field-of-view (LAFOV) systems have enhanced clinical practice by leveraging their technological advantages and have...
3.
Kulkarni H, Maupin K, Brennan T, Forsberg J, Rogers D, Olson M, et al.
J Nucl Med
. 2024 Sep;
65(11):1815.
PMID: 39237345
No abstract available.
4.
Kluge A, Baum R, Bitterlich N, Kulkarni H, Schorr-Neufing U, van Echteld C
Cancer Biother Radiopharm
. 2024 Jun;
39(7):541-550.
PMID: 38905126
In a prior, retrospective study, 76% of patients with advanced neuroendocrine tumors undergoing Lu-DOTATOC molecular radiotherapy (MRT) showed their best response within 8 months from the first MRT cycle. In...
5.
Liu Q, Kulkarni H, Zhao T, Schuchardt C, Chen X, Zhu Z, et al.
Clin Nucl Med
. 2023 Feb;
48(3):221-227.
PMID: 36723881
Purpose: Progressive metastatic medullary thyroid carcinoma (MTC) is often characterized by rapid disease progression and poor prognosis, with only few therapeutic options available. Peptide receptor radionuclide therapy (PRRT) has demonstrated...
6.
7.
Langbein T, Kulkarni H, Schuchardt C, Mueller D, Volk G, Baum R
Diagnostics (Basel)
. 2022 Aug;
12(8).
PMID: 36010276
Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high uptake of the radiopharmaceutical in the salivary glands (SG)...
8.
Schuchardt C, Zhang J, Kulkarni H, Chen X, Muller D, Baum R
J Nucl Med
. 2021 Dec;
63(8):1199-1207.
PMID: 34887335
The objective of this study was to determine the safety, kinetics, and dosimetry of the Lu-labeled prostate-specific membrane antigen (PSMA) small molecules Lu-PSMA I&T and Lu-PSMA-617 in a large cohort...
9.
Zhang J, Kulkarni H, Baum R
Clin Nucl Med
. 2021 Jul;
46(12):1030-1031.
PMID: 34238802
Somatostatin receptor-targeted α-therapy using α-emitter 225Ac-labeled somatostatin analogs has been suggested as a treatment option in advanced metastatic neuroendocrine tumors (NETs) failing treatment with β-emitters, such as 177Lu or 90Y....
10.
Baum R, Schuchardt C, Singh A, Chantadisai M, Robiller F, Zhang J, et al.
J Nucl Med
. 2021 Jun;
63(3):415-423.
PMID: 34168013
Fibroblast activation protein (FAP) is a promising target for diagnosis and therapy of numerous malignant tumors. FAP-2286 is the conjugate of a FAP-binding peptide, which can be labeled with radionuclides...